NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to control advanced lung cancer in major trial
Disease control Recruiting nowThis study tests whether adding an experimental drug (telisotuzumab adizutecan) to a standard targeted therapy (osimertinib) works better than standard treatment for people with a certain type of advanced lung cancer (EGFR-mutated non-squamous NSCLC). About 854 adults will receiv…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New hope for hard-to-treat lung cancer: drug duo targets HER2
Disease control Recruiting nowThis study tests a combination of two drugs, BL-M07D1 and pembrolizumab, in people with advanced HER2-positive non-small cell lung cancer that cannot be removed by surgery. The goal is to see if the treatment shrinks tumors and controls the disease. About 80 adults aged 18 to 75 …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for lung cancer patients when targeted drugs fail
Disease control Recruiting nowThis study tests a new drug called JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow and hide from the immune system. It is given together with chemotherapy or another experimental drug (JS212) to people with advanced non-small cell lung cancer whose tumors …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for lung cancer: could rilvegostomig beat current standard?
Disease control Recruiting nowThis study compares a new drug, rilvegostomig, against the current standard pembrolizumab, both given with chemotherapy, as a first treatment for people with advanced non-squamous non-small cell lung cancer that has a protein called PD-L1. The goal is to see if the new combinatio…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Could a cheaper keytruda copy work just as well for lung cancer?
Disease control Recruiting nowThis study compares a new, potentially more affordable drug called MB12 (a biosimilar to Keytruda) to the original Keytruda, both given with chemotherapy, as a first treatment for people with advanced stage IV non-squamous non-small cell lung cancer. About 726 adults who have not…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for HER2-mutant lung cancer: phase 3 trial pits targeted drug against chemo
Disease control Recruiting nowThis study compares a new drug, BL-M07D1, to standard chemotherapy plus immunotherapy for people with advanced or spreading non-squamous non-small cell lung cancer that has a specific HER2 gene mutation. About 440 adults will be randomly assigned to receive either BL-M07D1 or the…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
Brazilian lung cancer study reveals Real-World treatment gaps
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 adults in Brazil with advanced non-squamous lung cancer whose first chemotherapy failed. Researchers want to understand what treatments doctors use next and how patients fare. No new drugs are tested—the goal is to learn from real-w…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:50 UTC